ADMA Biologics

Moat components and scores: Intangible assets 70. ASCENIV and BIVIGAM are FDA‑approved biologics with brand acceptance in PI, and ASCENIV is protected by patented donor screening and plasma pooling methodology referenced in company materials.

These are helpful but not impregnable like a composition‑of‑matter drug patent. (Weight 20 percent) Switching costs 75. Once stabilized, PI patients and sites of care are reluctant to switch IVIG brands due to tolerability, reimbursement, and formulary dynamics, creating moderate switching frictions rather than absolute lock‑in. (Weight 30 percent) Network effects 20. No meaningful network effects. (Weight 10 percent) Cost advantages 65. Yield‑enhanced production and a self‑supply plasma network support structurally better unit economics than in ADMA’s past.

FDA lot release of yield‑enhanced batches began in late 2025, and Q1 2026 margin reached about 71 percent. (Weight 20 percent) Efficient scale 80. Plasma fractionation is capital and compliance intensive, with few scaled players and high FDA oversight.

ADMA operates a Boca Raton facility and a network of FDA‑licensed plasma centers concentrated in the Southeast, with enough internal supply to support its portfolio. (Weight 20 percent) Weighted together these support a durable but not indestructible moat anchored in regulatory barriers, quality systems, and growing production know‑how.

Key erosion risks: standard IG price resets; regulatory actions at plants or centers; and larger competitors exerting purchasing and contracting power.